Utah Medical Board calls for suspension of AI prescription renewal pilot
Utah's medical licensing board called for immediate suspension of a state-run AI prescription renewal program operated by Doctronic, citing lack of physician oversight and potential risks from patients remaining on outdated medications. The program, which began in October 2025 and covers approximately 192 medications, autonomously renews prescriptions based on brief patient questionnaires, but the board was not consulted before launch.
What happened
Utah's Department of Commerce and Office of Artificial Intelligence Policy launched a pilot program in October 2025 that allows Doctronic AI to autonomously renew prescriptions for approximately 192 routine medications without physician oversight, based on brief patient questionnaires.
On April 20, 2026, the Utah Medical Licensing Board sent a letter calling for immediate suspension of the program, stating it was not notified before launch and that prescription refills require physician reassessment for safety and clinical reasons.
Reported impact
The Medical Licensing Board warned that patients could remain on outdated or suboptimal therapy for months or years if medications are refilled without clinical reassessment, and that prescription refills require monitoring for side effects, contraindications, and new drug interactions.
The board stated the program 'potentially places Utah citizens at risk' but did not report actual patient harm.
Index analysis
The Medical Licensing Board expressed concern that prescription refill oversight by AI lacked the clinical decision-making capacity that licensed practitioners provide, noting decades of collective medical expertise across specialties positions the board to assess such risks.
The Department of Commerce responded that licensed physicians review all prescriptions and that no autonomous prescribing occurs, contradicting the stated program design of autonomous AI-generated renewals.
Governance controls
The Medical Licensing Board was not consulted before the program began and only learned of it after launch, indicating a governance gap between the state's AI implementation and medical licensing oversight.
The Department of Commerce stated licensed professionals were consulted before launch and that the program would be rigorously evaluated, though the board maintained that proper oversight mechanisms should be in place before deployment rather than as a monitoring step.
Classification
Sources and evidence
Sources not yet published
This record was researched and written by the Index from original reporting. Its sources are still being verified by an editor, and they are listed here once that check is complete. Until then the record carries no reviewer.